AU2021900392A0 - Methods of assessing risk of developing a severe response to Coronavirus infection - Google Patents

Methods of assessing risk of developing a severe response to Coronavirus infection

Info

Publication number
AU2021900392A0
AU2021900392A0 AU2021900392A AU2021900392A AU2021900392A0 AU 2021900392 A0 AU2021900392 A0 AU 2021900392A0 AU 2021900392 A AU2021900392 A AU 2021900392A AU 2021900392 A AU2021900392 A AU 2021900392A AU 2021900392 A0 AU2021900392 A0 AU 2021900392A0
Authority
AU
Australia
Prior art keywords
developing
methods
coronavirus infection
assessing risk
severe response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2021900392A
Inventor
Richard Allman
Gillian Sue Dite
Nicholas Mark Murphy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetic Technologies Ltd
Original Assignee
Genetic Technologies Ltd
Filing date
Publication date
Application filed by Genetic Technologies Ltd filed Critical Genetic Technologies Ltd
Publication of AU2021900392A0 publication Critical patent/AU2021900392A0/en
Priority to EP21813074.8A priority Critical patent/EP4158067A1/en
Priority to AU2021281702A priority patent/AU2021281702A1/en
Priority to MX2022014931A priority patent/MX2022014931A/en
Priority to PCT/AU2021/050507 priority patent/WO2021237292A1/en
Priority to CA3179313A priority patent/CA3179313A1/en
Priority to JP2022572759A priority patent/JP2023527834A/en
Priority to IL298097A priority patent/IL298097A/en
Priority to CN202180048201.7A priority patent/CN116134152A/en
Priority to KR1020227045938A priority patent/KR20230019872A/en
Priority to US17/368,471 priority patent/US11257569B1/en
Priority to US17/667,282 priority patent/US20220246242A1/en
Abandoned legal-status Critical Current

Links

AU2021900392A 2020-05-27 2021-02-17 Methods of assessing risk of developing a severe response to Coronavirus infection Abandoned AU2021900392A0 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
KR1020227045938A KR20230019872A (en) 2020-05-27 2021-05-26 How to Assess Your Risk of Severe Reactions to Coronavirus Infection
CA3179313A CA3179313A1 (en) 2020-05-27 2021-05-26 Methods of assessing risk of developing a severe response to coronavirus infection
AU2021281702A AU2021281702A1 (en) 2020-05-27 2021-05-26 Methods of assessing risk of developing a severe response to Coronavirus infection
MX2022014931A MX2022014931A (en) 2020-05-27 2021-05-26 Methods of assessing risk of developing a severe response to coronavirus infection.
PCT/AU2021/050507 WO2021237292A1 (en) 2020-05-27 2021-05-26 Methods of assessing risk of developing a severe response to coronavirus infection
EP21813074.8A EP4158067A1 (en) 2020-05-27 2021-05-26 Methods of assessing risk of developing a severe response to coronavirus infection
JP2022572759A JP2023527834A (en) 2020-05-27 2021-05-26 How to Assess Your Risk of Developing a Severe Response to Coronavirus Infection
IL298097A IL298097A (en) 2020-05-27 2021-05-26 Methods of assessing risk of developing a severe response to coronavirus infection
CN202180048201.7A CN116134152A (en) 2020-05-27 2021-05-26 Method for assessing risk of producing a severe response to coronavirus infection
US17/368,471 US11257569B1 (en) 2020-05-27 2021-07-06 Methods of assessing risk of developing a severe response to coronavirus infection
US17/667,282 US20220246242A1 (en) 2020-05-27 2022-02-08 Methods of assessing risk of developing a severe response to coronavirus infection

Publications (1)

Publication Number Publication Date
AU2021900392A0 true AU2021900392A0 (en) 2021-03-04

Family

ID=

Similar Documents

Publication Publication Date Title
EP3930697A4 (en) Inhibitors of integrated stress response pathway
EP3982965A4 (en) Modulators of integrated stress response pathway
EP3990983A4 (en) Bake strategies to enhance lithographic performance of metal-containing resist
EP3982949A4 (en) Inhibitors of sarm1
EP3980011A4 (en) Inhibitors of sarm1
AU2021900392A0 (en) Methods of assessing risk of developing a severe response to Coronavirus infection
AU2020903536A0 (en) Methods of assessing risk of developing a severe response to coronavirus infection
AU2020902052A0 (en) Methods of assessing risk of developing a severe response to Coronavirus infection
AU2020901739A0 (en) Methods of assessing risk of developing a severe response to Coronavirus infection
EP3991062A4 (en) Entity engine of a computing platform
DK4135756T3 (en) C1 esterase inhibitor to treat respiratory distress related to a coronavirus infection
EP4017973A4 (en) Biosynthesis of eriodictyol
EP4065502A4 (en) Main girder of bridge crane
GB2601956B (en) Techniques to identify segments of information space through active adaption to environment context
GB202017922D0 (en) Optimization of dataset
EP3956629A4 (en) Measurement system and a method of diffracting light
TWI799707B (en) A kind of polymerizable compound and application
MA56445A (en) SUBSTITUTED TETRAHYDROISOQUINOLINE DERIVATIVE USED AS A POSITIVE ALLOSTERIC MODULATOR OF D1
EP3994443A4 (en) Measuring deformation threshold of produce
EP4078364A4 (en) Migration of vnfs to vims
EP3924324A4 (en) L-pipecolic acid cocrystal of cannabidiol
AU2023901140A0 (en) Inhibition of coronavirus
AU2022901634A0 (en) Suspension bridge
AU2020904342A0 (en) Crawler bridge
AU2020900562A0 (en) Inhibitors of necroptosis